152 related articles for article (PubMed ID: 20179179)
41. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
Márk Á
Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
43. Epigenetic Regulation of the PTEN-AKT-RAC1 Axis by G9a Is Critical for Tumor Growth in Alveolar Rhabdomyosarcoma.
Bhat AV; Palanichamy Kala M; Rao VK; Pignata L; Lim HJ; Suriyamurthy S; Chang KT; Lee VK; Guccione E; Taneja R
Cancer Res; 2019 May; 79(9):2232-2243. PubMed ID: 30833420
[TBL] [Abstract][Full Text] [Related]
44. Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice.
Jetzt A; Howe JA; Horn MT; Maxwell E; Yin Z; Johnson D; Kumar CC
Cancer Res; 2003 Oct; 63(20):6697-706. PubMed ID: 14583464
[TBL] [Abstract][Full Text] [Related]
45. Regulation of osteoclast apoptosis and motility by small GTPase binding protein Rac1.
Fukuda A; Hikita A; Wakeyama H; Akiyama T; Oda H; Nakamura K; Tanaka S
J Bone Miner Res; 2005 Dec; 20(12):2245-53. PubMed ID: 16294277
[TBL] [Abstract][Full Text] [Related]
46. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.
Venkatanarayan A; Raulji P; Norton W; Chakravarti D; Coarfa C; Su X; Sandur SK; Ramirez MS; Lee J; Kingsley CV; Sananikone EF; Rajapakshe K; Naff K; Parker-Thornburg J; Bankson JA; Tsai KY; Gunaratne PH; Flores ER
Nature; 2015 Jan; 517(7536):626-30. PubMed ID: 25409149
[TBL] [Abstract][Full Text] [Related]
47. Phosphatidylinositol 3'-kinase signaling pathway is essential for Rac1-induced hypoxia-inducible factor-1(alpha) and vascular endothelial growth factor expression.
Xue Y; Li NL; Yang JY; Chen Y; Yang LL; Liu WC
Am J Physiol Heart Circ Physiol; 2011 Jun; 300(6):H2169-76. PubMed ID: 21357506
[TBL] [Abstract][Full Text] [Related]
48. An anti-cancer WxxxE-containing azurin polypeptide inhibits Rac1-dependent STAT3 and ERK/GSK-3β signaling in breast cancer cells.
Zhang Z; Luo Z; Min W; Zhang L; Wu Y; Hu X
Oncotarget; 2017 Jun; 8(26):43091-43103. PubMed ID: 28549350
[TBL] [Abstract][Full Text] [Related]
49. Blockade of Rac1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein.
Yoshida T; Zhang Y; Rivera Rosado LA; Chen J; Khan T; Moon SY; Zhang B
Mol Cancer Ther; 2010 Jun; 9(6):1657-68. PubMed ID: 20515940
[TBL] [Abstract][Full Text] [Related]
50. Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
Fang D; Chen H; Zhu JY; Wang W; Teng Y; Ding HF; Jing Q; Su SB; Huang S
Oncogene; 2017 Mar; 36(11):1546-1558. PubMed ID: 27617576
[TBL] [Abstract][Full Text] [Related]
51. Rac1/Cdc42 and RhoA GTPases antagonistically regulate chondrocyte proliferation, hypertrophy, and apoptosis.
Wang G; Beier F
J Bone Miner Res; 2005 Jun; 20(6):1022-31. PubMed ID: 15883643
[TBL] [Abstract][Full Text] [Related]
52. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
Moser C; Lang SA; Kainz S; Gaumann A; Fichtner-Feigl S; Koehl GE; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Nov; 6(11):2868-78. PubMed ID: 18025273
[TBL] [Abstract][Full Text] [Related]
53. Oncogene-induced senescence as an initial barrier in lymphoma development.
Braig M; Lee S; Loddenkemper C; Rudolph C; Peters AH; Schlegelberger B; Stein H; Dörken B; Jenuwein T; Schmitt CA
Nature; 2005 Aug; 436(7051):660-5. PubMed ID: 16079837
[TBL] [Abstract][Full Text] [Related]
54. Long noncoding RNA LCAT1 functions as a ceRNA to regulate RAC1 function by sponging miR-4715-5p in lung cancer.
Yang J; Qiu Q; Qian X; Yi J; Jiao Y; Yu M; Li X; Li J; Mi C; Zhang J; Lu B; Chen E; Liu P; Lu Y
Mol Cancer; 2019 Nov; 18(1):171. PubMed ID: 31779616
[TBL] [Abstract][Full Text] [Related]
55. Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer.
Wang L; Wang J; Xiong H; Wu F; Lan T; Zhang Y; Guo X; Wang H; Saleem M; Jiang C; Lu J; Deng Y
EBioMedicine; 2016 May; 7():50-61. PubMed ID: 27322458
[TBL] [Abstract][Full Text] [Related]
56. Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.
Venkatanarayan A; Raulji P; Norton W; Flores ER
Cell Cycle; 2016; 15(2):164-71. PubMed ID: 26652033
[TBL] [Abstract][Full Text] [Related]
57. Maspin controls mammary tumor cell migration through inhibiting Rac1 and Cdc42, but not the RhoA GTPase.
Shi HY; Stafford LJ; Liu Z; Liu M; Zhang M
Cell Motil Cytoskeleton; 2007 May; 64(5):338-46. PubMed ID: 17301947
[TBL] [Abstract][Full Text] [Related]
58. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway.
Liu S; Yu M; He Y; Xiao L; Wang F; Song C; Sun S; Ling C; Xu Z
Hepatology; 2008 Jun; 47(6):1964-73. PubMed ID: 18506888
[TBL] [Abstract][Full Text] [Related]
59. PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers.
Li Y; Chitnis N; Nakagawa H; Kita Y; Natsugoe S; Yang Y; Li Z; Wasik M; Klein-Szanto AJ; Rustgi AK; Diehl JA
Cancer Discov; 2015 Mar; 5(3):288-303. PubMed ID: 25582697
[TBL] [Abstract][Full Text] [Related]
60. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
